Stay updated with breaking news from Code Biotherapeutics Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ZÜRICH, SWITZERLAND / ACCESSWIRE / May 8, 2023 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP)(NASDAQ:NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage biopharmaceutical company focused on the discovery and
Press Release 4BIO Capital Portfolio Company Code Biotherapeutics Closes Upsized and Oversubscribed $75 Million Series A Financing 7 June 2022 London & Greater Philadelphia - 4BIO Capital
4BIO Capital Co-leads $10 Million Seed Financing in Code Biotherapeutics 04/20/2021 | 09:00am EDT Send by mail : Message : 20 April 2021 LONDON & BOSTON – 4BIO Capital (“4BIO” or “the Group”), an international venture capital firm focused solely on the advanced therapies sector, today announces that it has co-led a $10 million Seed financing round in Code Biotherapeutics, Inc. (“Code Bio” or the ”Company”), a next generation gene therapy company pioneering the development of targeted non-viral gene therapies for rare and prevalent genetic diseases. 4BIO actively participated...
4Bio Capital: 4BIO Capital Co-leads $10 Million Seed Financing in Code Biotherapeutics 20 April 2021 LONDON & BOSTON - 4BIO Capital ("4BIO" or "the Group"), an international venture capital firm focused solely on the advanced therapies sector, today announces that it has co-led a $10 million Seed financing round in Code Biotherapeutics, Inc. ("Code Bio" or the "Company"), a next generation gene therapy company pioneering the development of targeted non-viral gene therapies for rare and prevalent genetic diseases. 4BIO actively participated in the start-up process and co-led the financing alon...